Physician profile
Nimra Sarfaraz
NPI 1104088780
$2,563.14
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $216 · 2021: $639 · 2022: $1,091 · 2023: $66.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $637.59 | 2019-2023 | Veltassa |
| Daiichi Sankyo INC. | $491.58 | 2019-2023 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $420.28 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $231.13 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $193.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $180.87 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $124.14 | 2022 | |
| Opko Pharmaceuticals, LLC | $76.96 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $39.09 | 2022 | |
| Travere Therapeutics, INC. | $20.40 | 2022 | |
| Fresenius USA Marketing, INC. | $13.78 | 2019 | |
| Akebia Therapeutics INC | $8.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimra Sarfaraz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.